Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Patidegib - Sol-Gel Technologies

Next Previous
Drug Profile

Patidegib - Sol-Gel Technologies

Alternative Names: BBP-009; FIN-5; IPI-926; Patidegib topical gel - PellePharm; Patidegib-hydrochloride; Saridegib; Saridegib-hydrochloride; SGT-610

Latest Information Update: 24 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Infinity Pharmaceuticals
  • Developer Infinity Pharmaceuticals; PellePharm; Sol-Gel Technologies
  • Class Antineoplastics; Naphthols; Pyridines; Small molecules; Spiro compounds; Sulfonamides; Veratrum alkaloids
  • Mechanism of Action SMO protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chondrosarcoma; Basal cell nevus syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Basal cell nevus syndrome
  • Phase II Basal cell cancer
  • Discontinued Chondrosarcoma; Head and neck cancer; Myelofibrosis; Pancreatic cancer

Most Recent Events

  • 20 Aug 2026 Sol-Gel Technologies announces intention to launch Patidegib for Basal Cell Nevus Syndrome in the US
  • 20 Aug 2026 Sol-Gel Technologies plans a pivotal registration phase III trial for Basal cell cancer (Topical, Gel) in late 2027 or the first half of 2028
  • 31 May 2026 Sol Gel Technologies receives notice of allowance for patidegib in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top